Brief: Phase II/III Clinical Trial Of Simcere's XIANNUOXIN Completes Patients Enrollment
20/12/2022 11:38
Dec 20 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING
ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT
Source text for Eikon: ID:nPn2QFPB7a
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660